Scope and edition
The tenth edition, published 30 January 2026, covers import relief, approved contract manufacturing, research grants and services, prototypes, input tax and reverse charge. The twenty-two-page document distinguishes relief, disregarded supplies and zero-rating: they are different mechanisms, each with its own conditions.
Clinical research materials: imports and disposal
A local intermediary importing for an overseas sponsor may lack ordinary input-tax recovery or MES entitlement. Relief can cover medicinal and therapeutic products and their placebos, and from 16 December 2021 Class 2 cell, tissue or gene therapy products and placebos. They must be imported for regulated local trials, re-export for overseas trials or local destruction/disposal; their inability to be legally traded or sold supports the relief. Other importers may also apply. Customs sets the detailed scope and application requirements; local disposal must comply with NEA toxic-industrial-waste regulations.
ACMT: qualifying manufacturers and client exclusions
Active Pharmaceutical Ingredient contract manufacturers may apply; other biomedical segments are considered case by case if their model and eligibility fit. Ordinary rules otherwise tax local manufacturing services and locally purchased materials that an unregistered foreign client cannot recover. Privileges exclude local clients and GST-registered overseas clients, except pay-only overseas vendors under OVR.
Four ACMT benefits and the supply-chain diagram
Subject to the scheme conditions, disregard value-added services including processing, assembly, quality control and functional testing under consignment, modified turnkey and full turnkey models; disregard services relating to failed/excess production; suspend import GST on the manufacturer’s own and client-owned goods; and recover GST on locally purchased client goods delivered for qualifying value-add. Local sale of finished goods requires accounting on the client’s behalf on the goods’ sale value. A manufacturer also selling the raw material still accounts for its own output tax: recovery on behalf is separate. The diagram also distinguishes exports, delivery for further value-add/storage before export, and disposal of failed/excess goods.
Research grants: when a payment is consideration
An outright grant with nothing supplied to the grantor is outside GST. Identifiable tangible direct benefits, such as IP rights, rights to use results or a share of research income, create consideration. Account for GST at 9/109 of the benefits’ open-market value; if that value cannot be obtained or separately identified, use the full grant. The source’s commercial-rights example falls into this taxable category.
Grant examples: accountability and public education
Progress reporting and grantor access merely used to monitor funding and ensure accountability need not be direct benefits. Publishing a lifestyle-disease study on a nonprofit grantor’s website for public education benefits the public rather than the grantor specifically. These two examples therefore do not require output GST on the grants, unlike commercial rights supplied in exchange.
Overseas R&D: both statutory conditions
Section 21(3)(j) requires contractual supply to an overseas person and direct benefit to an overseas person absent from Singapore when performed, or from 1 January 2020 to a GST-registered Singapore beneficiary. The service must also not be directly connected with Singapore goods or land. Determine actual consumers from the contract and service flow; potential secondary beneficiaries do not become direct beneficiaries merely through later use.
All three research-agreement examples
Preliminary results used by an overseas institution to develop a vaccine can qualify for zero-rating. Results delivered instead to its GST-registered local subsidiary were taxable before 2020 but may qualify from 2020, with the non-full-recovery subsidiary considering reverse charge on amounts charged by the overseas institution. Where an overseas institution publishes results worldwide as required by its funding foundation, that institution remains the direct beneficiary; Singapore readers and researchers are secondary recipients. Each outcome still requires the absence of direct connection with local goods or land.
Clinical trials on people or animals
Fact-finding trials producing an analytical report are not treated as directly connected with the human or animal subjects, who serve as research tools. Example 4 tests a drug on animals and reports efficacy to the overseas pharmaceutical company: the trial service can be zero-rated under the stated international-service conditions.
Specimen and blood testing: all three conditions
The broader treatment applies if testing is for fact-finding with a report as outcome, adds no value or enhancement to the specimens, and the specimens have no commercial value and are discarded afterward. Example 5 tests blood-cell count, sugar and cholesterol for foreign clinics and disposes of the samples: this is not directly connected with local goods and can qualify for zero-rating.
Prototypes: five indicators of knowledge creation
A tangible prototype is a good, but can merely be a tool for creating new knowledge. Examine research scope, the customer’s expected main deliverable, creation of new technology, creation of IP such as patents, and lack of commercial sale of the prototype. A new prototype did not exist when research began; an existing one can also be a tool. Indicators are contextual, not absolute or exhaustive. A physical report does not turn intangible know-how into a supply of goods.
Quality-control testing and manufacture are different
QC on newly made Singapore medical devices concerns the goods themselves and is standard-rated. Section 21(3)(k) can instead cover prescribed services on a sample drawn from goods outside Singapore when performed, subject to the stated business-capacity and beneficiary conditions. Producing a prototype to a ready formula without adding knowledge is treated as goods: standard-rate local delivery, zero-rate a qualifying export. Example 7 produces a tablet to supplied instructions and is locally taxable.
Appendix 1: all four prototype scenarios
Developing a new flu-drug formula with a nonsaleable verification prototype can be zero-rated. Enhancing an existing formula to remove drowsiness can also qualify: old samples receive no value-add and are discarded, while the new prototype verifies the patented enhanced formula. QC on commercial batches for Singapore distribution is standard-rated. Manufacturing a prototype to customer specifications for delivery to a related Singapore company is also standard-rated, regardless of prototype value.
All six ordinary input-tax conditions
Local purchases must be contractually supplied to the claimant and imports must show it as rightful importer; goods/services must serve its business and taxable supplies or qualifying out-of-scope supplies; valid invoices/import permits must support the claim; Regulations 26/27 must not disallow it; and reasonable steps must establish that the transaction is not part of missing-trader fraud. The cited disallowed categories include club subscriptions, medical/accident insurance, medical costs, family benefits and motor cars.
Failed commercialisation: preserve the original evidence
A firm original intention to make taxable supplies, documented by contracts or plans, can support retaining previously claimed input tax when uncontrollable genuine events prevent supply. Example 8 has manufacturing contracts and marketing plans, but new safety regulations prevent drug approval: no repayment is required. Without such proof repay the earlier claim; costs after taxable-supply intention ceases do not qualify.
Nontaxable grants do not automatically restrict recovery
A business wholly making taxable supplies may recover qualifying input tax in full even when partly funded by outright nontaxable grants. Example 9 supplies fee-based R&D to local and foreign businesses plus public-agency grants: full recovery remains subject to ordinary conditions. Mixed business/nonbusiness activities require apportionment to taxable activities.
Imported services, low-value goods and source history
From 2020 reverse charge may apply where the business or GST group lacks full input-tax recovery, with specified service exclusions and ordinary recovery of the corresponding tax. From 2023 it extends to imported low-value goods, except purchases directly attributable to taxable supplies, across local/foreign suppliers, marketplaces and redeliverers regardless of registration. The revision history records 2021 input-tax updates,2022 CTGT/LVG changes,2023 eight-percent and 2024 nine-percent rates, and 2026 editorial changes. Unclear cases can be submitted with full facts to IRAS GST Division through Contact Us.
Official source
This article independently explains the substantive contents of the official PDF, including the relevant conditions, procedures and annexes. The linked document remains the authoritative source for its original wording, and later changes should be checked separately.
Read the official PDF ↗